From the ∗Arizona Arthritis and Rheumatology Research, PLLC, Phoenix, AZ
†Division of Allergy, Immunology, and Rheumatology, University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY
‡Sun Pharmaceutical Industries, Inc, Princeton, NJ
§Servicio de Reumatología, Hospital CIMA Sanitas, Paseo Manuel Girona, Barcelona, Spain.
Contributors: All authors contributed to data interpretation and manuscript development, critically reviewed each draft for intellectual content, and approved the final version for submission.
Competing interests: E.P. has nothing to disclose; R.C.C. receives consultation fees from Sun Pharma; S.J.R. and S.L.Y. are employees of Sun Pharmaceutical Industries, Inc.; F.J.G.F. has received research grants, consulting fees, and/or speaker fees from AbbVie, Eli Lilly, Gedeon Richter, MedImmune, Nichi-Iko, Pfizer, Sanofi-Aventis, Takeda, and Union Chimique Belge.
Funding: The study was funded by Sun Pharma. Analyses and medical writing support were funded by Sun Pharma, Princeton, NJ.
Ethics approval: The study protocol (online supplemental file) was approved by Independent Ethics Committees or Institutional Review Boards at each site. The trial was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines.
Data availability statement: Data and other documents will be made available after publication, with no end date, to anyone who submits a reasonable request to the study sponsor.
Correspondence: Eric Peters, MD, Arizona Arthritis and Rheumatology Associates PC, 4550 E Bell Rd Ste 170, Phoenix, AZ 85032. E-mail: [email protected].
Supplemental digital content is available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal’s Web site (www.jclinrheum.com).